Eli Lilly delivered a stunning financial performance that exceeded even the most optimistic market expectations, driven by unprecedented demand for its ...

Gov. Glenn Youngkin announced a landmark partnership Friday with AstraZeneca, Lilly and Merck to create the nation’s largest ...

AstraZeneca, Eli Lilly and Merck committed $120 million to develop an advanced pharmaceutical manufacturing training center in Central Virginia.

Eli Lilly, Zyrtec and Astellas Pharma recently invested in celeb partnerships to raise awareness about conditions.

Alnylam Pharmaceuticals, Inc. is rated Hold due to high expectations, competitive threats, and revenue expansion. Learn more ...

The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company ...

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

Takeda tightened its pipeline in the third quarter. Innovent Biologics reported a head-to-head win against semaglutide in a Chinese phase 3 trial. | Takeda tightened its pipeline in the third quarter.

Recent health news highlights include Calley Means leaving his advisory role at the White House, Cipla CEO Umang Vohra ...

Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited bid to acquire obesity treatment maker Metsera, topping an offer from US ...